* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
IJGC Podcast
The International Journal of Gynecological Cancer (IJGC) podcast explores the latest research on detection, prevention, diagnosis, and treatment of gynecologic malignancies. Enjoy interviews with leading experts as they discuss novel and relevant topics in the field of gynecologic cancer. Join Editor-in-Chief Dr. Pedro Ramirez and his guests for an interactive and educational experience. Subscribe now or listen on your favourite podcast platform. IJGC - ijgc.bmj.com - is the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.
Episodes
Tuesday Jul 27, 2021
Tuesday Jul 27, 2021
In this episode of the IJGC Podcast, Editorial Fellows Cecilia Darin and Natalia Rodriguez discuss the contents of the August issue of IJGC in Spanish.
Friday Jul 23, 2021
Friday Jul 23, 2021
In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discusses the contents of the June issue of IJGC in Spanish.
Friday Jul 23, 2021
Friday Jul 23, 2021
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Shannon Westin to discuss Phase II Trial of IUD in conservative management of endometrial cancer. Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. She is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies.
Shannon Westin (@ShannonWestin / @mdandersonnews)
Highlights:
1. A fertility-sparing, non-surgical approach is increasingly necessary for individuals diagnosed with early endometrial neoplasia due to increasing prevalence of significant comorbidities and proportion of premenopausal women diagnosed with this disease.
2. Out of 57 treated patients, 47 were evaluable and 12-month response rate was 83% overall (90.6% for complex atypical hyperplasia and 66.7% for grade 1 endometrioid endometrial cancer).
3. Adverse events associated with the IUD were mild, and quality of life was not negatively impacted.
4. This study used a rigorous 12-month endpoint to demonstrate durable response rates in women with early endometrial neoplasia and identified potential biomarkers for therapy resistance.
Friday Jul 16, 2021
Friday Jul 16, 2021
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Dimitrios Nasioudis to discuss the impact of SLN biopsy versus lymphadenectomy in endometrial cancer. Dr. Nasioudis is a resident at the Hospital of the University of Pennsylvania, Philadelphia. His current interests include population science and outcomes research with an emphasis on rare gynecologic tumors.
Dimitrios Nasioudis (@Dnasioudis / @PennMedicine)
Highlights:
- Sentinel lymph node biopsy has been established as a minimalistic approach to endometrial cancer staging, with excellent diagnostic accuracy.
- Data on the long-term oncologic and patient reported outcomes are greatly warranted.
- For patients with stage IIIC endometrial cancer, based on a large dataset, overall survival was comparable between the sentinel lymph node biopsy alone and systematic lymphadenectomy groups.
Wednesday Jul 14, 2021
Wednesday Jul 14, 2021
In this episode of the IJGC Podcast, Editorial Fellows Anna Collins and Nicolò Bizzarri discuss the contents of the July issue of IJGC in English.
Monday Jul 12, 2021
Monday Jul 12, 2021
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Roni Nitecki to discuss pregnancy outcomes after ovarian cancer. Dr. Nitecki is a gynecologic oncology fellow at the MD Anderson Cancer Center. She received her MD from Dartmouth medical school in 2015 and completed her residency in obstetrics and gynecology at Brigham and Women's Hospital and Massachusetts General Hospital in 2019.
Highlights
- Fertility considerations in young women with ovarian cancer are becoming increasingly relevant.
- Fear of pregnancy and adverse obstetric outcomes may be one reason that women do not pursue pregnancy after fertility sparing surgery.
- Counseling about pregnancy outcomes is an important part of shared decision-making about fertility sparing surgery for ovarian cancer.
- In this study, patients who conceived at least 3 months after fertility sparing surgery for ovarian cancer did not have an increased risk of adverse obstetric outcomes.
Thursday Jul 01, 2021
Thursday Jul 01, 2021
Andrew Clamp (@TheChristieNHS and @OfficialUoM)
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Andrew Clamp to discuss rucaparib maintenance in recurrent ovarian cancer (ARIEL3). Dr. Clamp is an author of “Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3,” the Lead Article for IJGC’s July 2021 issue. Dr. Clamp is a Consultant and Honorary Senior Lecturer in Medical Oncology subspecializing in the treatment of gynaecological cancers. He is Chief Investigator for the MRC ICON8 Trials Programme and leads the gynaecological cancers clinical research team at The Christie.
Highlights
- Rucaparib provides a clinically significant prolongation of progression-free survival when used as maintenance treatment for platinum-sensitive recurrent ovarian cancer.
- In the ARIEL3 trial, rucaparib extended progression-free survival versus placebo regardless of the length of the penultimate platinum-free interval, number of prior chemotherapy regimens or previous use of bevacizumab.
- After extended follow-up, rucaparib was well-tolerated and its safety profile was not impacted by prior treatment history.
- Maintenance PARP inhibitors should be considered for all PARP inhibitor naïve patients with recurrent high grade ovarian cancer after response to platinum-based chemotherapy.
Friday Jun 25, 2021
Friday Jun 25, 2021
In this episode of the IJGC Podcast, Editorial Fellows Anna Collins, Irina Tsibulak, Nicolò Bizzarri, Alex Mutombo, Enrique Chacon, and Arthur Hsu interview Professor Denis Querleu for an extended discussion of his experiences in gynecologic oncology, the importance of mentorship, and pathways for development in the field.
Friday Jun 18, 2021
Friday Jun 18, 2021
In this episode of the IJGC Podcast, Editorial Fellow Alex Mutombo discusses the contents of the June issue of IJGC in French.
Friday Jun 18, 2021
Friday Jun 18, 2021
In this episode of the IJGC Podcast, Editorial Fellow Irina Tsibulak discusses the contents of the June issue of IJGC in Russian.